Skip to content 
About the Project
Physician-Modified Endografts (PMEGs) are used in the management of complex aortic conditions, particularly in situations where standard treatment options may be limited.
The ESVS European Research Hub (ERH) is undertaking this initiative to develop a position statement and governance framework with the aim of supporting a consistent and transparent approach to their use.
We invite applications to join the Advisory Group for this project. The group will contribute to the development of an ERH-led structured position statement and governance framework. To ensure a balanced and multidisciplinary group, applications are encouraged from vascular specialists, methodologists, patient representatives, PMEG users, and regulatory stakeholders.
Role
Advisory Group members will provide expert input and contribute to discussions, document review, and development of the ERH-led drafting of the position statement.
Why participate?
- Contribute to shaping clinical and governance frameworks
- Collaborate with a multidisciplinary European expert group
- Support high-quality research and guidance development
Who should apply:
- Vascular specialists (surgery, interventional radiology, cardiology, angiology)
- PMEG experts
- Complex aortic experts
- Methodologists / statisticians
- Patient representatives
- Regulatory and notified body experts
Commitment:
- Online meetings
- One in-person meeting in Europe
- Active participation throughout the project
Key Dates:
- Application deadline: 23rd April 2026
How to take part:
- Complete the application form below
- Upload the required documents:
- Statement of interest (maximum 500 words)
- Declaration of Interest form
- CV
- Submit your application before 23 April 2026 (23:59 CEST)
Applications for this position are now closed.
I strongly believe that PMEGs represent a critical and evolving component of modern aortic therapy.
PMEGs may facilitate treatment in complex scenarios where standard options are limited; however, their current application is highly variable and not yet uniformly standardised. This highlights the importance of establishing clear indications, governance structures, and evidence-based guidance to avoid unstructured use.